1.Kim YJ., Chon S., Oh S., Woo JT., Kim SW., Rhee SY. Analysis of diabetes quality assessment findings and future directions for the appropriate management of diabetes in Korea. Korean J Intern Med. Published online March 15. 2017. DOI:
doi: 10.3904/kjim.2016.136.
2.Shaw JE., Sicree RA., Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010. 87:4–14.
Article
3.Hartemann-Heurtier A., Senneville E. Diabetic foot osteomyelitis. Diabetes Metab. 2008. 34:87–95.
Article
4.Berendt AR., Peters EJ., Bakker K., Embil JM., Eneroth M., Hinchliffe RJ, et al. Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment. Diabetes Metab Res Rev. 2008. 24(Suppl 1):S145-61.
Article
5.Lipsky BA., Berendt AR., Cornia PB., Pile JC., Peters EJ., Armstrong DG, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012. 54:e132–73.
6.Wininger DA., Fass RJ. Antibiotic-impregnated cement and beads for orthopedic infections. Antimicrob Agents Chemother. 1996. 40:2675–9.
Article
7.Roeder B., Van Gils CC., Maling S. Antibiotic beads in the treatment of diabetic pedal osteomyelitis. J Foot Ankle Surg. 2000. 39:124–30.
Article
8.Nelson CL., McLaren SG., Skinner RA., Smeltzer MS., Thomas JR., Olsen KM. The treatment of experimental osteomyelitis by surgical debridement and the implantation of calcium sulfate tobramycin pellets. J Orthop Res. 2002. 20:643–7. 9. LoGerfo FW, Coffman JD. Current concepts. Vascular and microvascular disease of the foot in diabetes. Implications for foot care. N Engl J Med. 1984;311: 1615-9.
Article
10.Cunningham A., Demarest G., Rosen P., DeCoster TA. Antibiotic bead production. Iowa Orthop J. 2000. 20:31–5.
11.Traub WH., Leonhard B. Heat stability of the antimicrobial activity of sixty-two antibacterial agents. J Antimicrob Chemother. 1995. 35:149–54.
Article
12.Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-third informational supplement. Wayne, PA: Clinical and Laboratory Standards Institute;2013.
13.Nelson CL., Hickmon SG., Harrison BH. Elution characteristics of gentamicin-PMMA beads after implantation in humans. Ortho- pedics. 1994. 17:415–6.
Article
14.Salvati EA., Callaghan JJ., Brause BD., Klein RF., Small RD. Reimplantation in infection. Elution of gentamicin from cement and beads. Clin Orthop Relat Res. 1986. 207:83–93.
15.Scharer BM., Sanicola SM. The in vitro elution characteristics of vancomycin from calcium phosphate-calcium sulfate beads. J Foot Ankle Surg. 2009. 48:540–2.
Article
16.Balsamo LH., Whiddon DR., Simpson RB. Does antibiotic elution from PMMA beads deteriorate after 1-year shelf storage? Clin Orthop Relat Res. 2007. 462:195–9.
Article
17.Calhoun JH., Mader JT. Antibiotic beads in the management of surgical infections. Am J Surg. 1989. 157:443–9.
Article
18.Shinsako K., Okui Y., Matsuda Y., Kunimasa J., Otsuka M. Effects of bead size and polymerization in PMMA bone cement on vancomycin release. Biomed Mater Eng. 2008. 18:377–85.
Article